Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion type Assertion NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_head.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion description "[Correlation of ITIH5 expression with clinical outcome revealed that patients with primary tumours retaining abundant ITIH5 expression had longer recurrence-free survival (RFS; P=0.037) and overall survival (OS; P=0.044), compared to those with reduced expression (mean RFS: 102 vs 78 months; mean OS: 120 vs 105 months).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_provenance.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion evidence source_evidence_literature NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_provenance.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion SIO_000772 17653090 NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_provenance.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion wasDerivedFrom befree-20140225 NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_provenance.
- NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_assertion wasGeneratedBy ECO_0000203 NP494100.RA9YylCAIXmVpxNePFlZ6XNrquUMX-pCo5Fk94csW0IzM130_provenance.